{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:41:04Z","timestamp":1790181664729,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Australian National Health and Medical Research Council for a Centre of Research Excellence","award":["APP2007007"],"award-info":[{"award-number":["APP2007007"]}]},{"name":"Australian National Health and Medical Research Council Investigator Grant","award":["APP2009736"],"award-info":[{"award-number":["APP2009736"]}]},{"name":"Advancing Queensland Clinical Fellowship"},{"name":"Australian National Health and Medical Research Council Investigator Award","award":["GNT1175509"],"award-info":[{"award-number":["GNT1175509"]}]},{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40262-022-01170-x","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T10:03:03Z","timestamp":1661853783000},"page":"1331-1343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-0292","authenticated-orcid":false,"given":"Mar\u00eda Patricia","family":"Hern\u00e1ndez-Mitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1368-8356","authenticated-orcid":false,"given":"Steven Y. C.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9214-6431","authenticated-orcid":false,"given":"Justin T.","family":"Denholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-2622","authenticated-orcid":false,"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3242-1155","authenticated-orcid":false,"given":"Asha C.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-8241","authenticated-orcid":false,"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2893-6954","authenticated-orcid":false,"given":"Balasubramanian","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-5822","authenticated-orcid":false,"given":"Thomas E.","family":"Hills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-7185","authenticated-orcid":false,"given":"Zoe","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2079-4437","authenticated-orcid":false,"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6131-8536","authenticated-orcid":false,"given":"Susan C.","family":"Morpeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"1170_CR1","doi-asserted-by":"crossref","unstructured":"Fehr AR, Perlman S. Coronaviruses: methods and protocols. In: Maier HJ (ed) Methods Mol Biol. Springer Science; 2015. p. 1\u2013282.","DOI":"10.1007\/978-1-4939-2438-7_1"},{"key":"1170_CR2","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects. bioRxiv. 2020;1\u201319.","DOI":"10.1101\/2020.04.22.054981"},{"key":"1170_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380.","journal-title":"Cell"},{"key":"1170_CR4","first-page":"1","volume":"12","author":"K Li","year":"2021","unstructured":"Li K, Meyerholz DK, Bartlett JA, McCray PB. The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19. Am Soc Microbiol. 2021;12:1\u201311.","journal-title":"Am Soc Microbiol"},{"key":"1170_CR5","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1128\/AAC.01043-16","volume":"60","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, et al. Identification of Nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016;60:6532\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1170_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Schroeder S, Kleine-Weber H, M\u00fcller MA, Drosten C, P\u00f6hlmann S. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64:1\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1170_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/jmv.26397","volume":"93","author":"M Ko","year":"2020","unstructured":"Ko M, Jeon S, Ryu W-S, Kim S. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate. J Med Virol. 2020;93:1403\u20138.","journal-title":"J Med Virol"},{"key":"1170_CR8","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 4413, Nafamostat [Internet]. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Nafamostat. Accessed 15 Nov 2021"},{"key":"1170_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1527-3466.1995.tb00213.x","volume":"13","author":"K Okajima","year":"1995","unstructured":"Okajima K, Uchiba M, Murakami K. Nafamostat Mesilate. Cardiovasc Drug Rev. 1995;13:51\u201365.","journal-title":"Cardiovasc Drug Rev"},{"key":"1170_CR10","unstructured":"Nichi-Iko Pharmaceutical Co. Ltd. Nafamostat mesylate Pharmaceutical Interview Form [Internet]. Ja; 2019. https:\/\/www.nichiiko.co.jp\/medicine\/file\/31050\/interview"},{"key":"1170_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","volume":"109","author":"D Minakata","year":"2019","unstructured":"Minakata D, Fujiwara SI, Ikeda T, Kawaguchi SI, Toda Y, Ito S, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109:141\u20136. https:\/\/doi.org\/10.1007\/s12185-018-02567-w (Springer Japan).","journal-title":"Int J Hematol"},{"key":"1170_CR12","doi-asserted-by":"publisher","unstructured":"Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol [Internet]. Springer Singapore; 2020. https:\/\/doi.org\/10.1007\/s12185-020-03029-y","DOI":"10.1007\/s12185-020-03029-y"},{"key":"1170_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/CIRCRESAHA.120.317447","volume":"127","author":"JD McFadyen","year":"2020","unstructured":"McFadyen JD, Stevens H, Peter K. The emerging threat of (Micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127:571\u201387.","journal-title":"Circ Res"},{"key":"1170_CR14","unstructured":"Nichi-Iko Pharmaceutical Co. L. Pharmaceutical interview form for FUTHAN 10 INJ., FUTHAN 50 INJ. 6th Edition [Internet]. 2019. https:\/\/www.nichiiko.co.jp\/medicine\/file\/31050\/interview"},{"key":"1170_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1039\/D0SC05064D","volume":"12","author":"T Hempel","year":"2021","unstructured":"Hempel T, Raich L, Olsson S, Azouz NP, Klingler AM, Hoffmann M, et al. Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat. Chem Sci. 2021;12:983\u201392.","journal-title":"Chem Sci"},{"key":"1170_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000420222","volume":"93","author":"Y Ohtake","year":"1991","unstructured":"Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol. 1991;93:215\u20137.","journal-title":"Contrib Nephrol"},{"key":"1170_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000002392","volume":"94","author":"J-Y Choi","year":"2015","unstructured":"Choi J-Y, Kang Y-J, Jang HM, Jung H-Y, Cho J-H, Park S-H, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk. A randomized clinical trial. Medicine (Baltimore). 2015;94:1\u20137.","journal-title":"Medicine (Baltimore)"},{"key":"1170_CR18","first-page":"767","volume":"27","author":"S Tsukagoshi","year":"2000","unstructured":"Tsukagoshi S. Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation. Jpn J Cancer Chemother. 2000;27:767\u201374.","journal-title":"Jpn J Cancer Chemother."},{"key":"1170_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40560-017-0244-x","volume":"5","author":"T Hirayama","year":"2017","unstructured":"Hirayama T, Nosaka N, Okawa Y, Ushio S, Kitamura Y, Sendo T, et al. AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study. J Intensive Care. 2017;5:1\u20137.","journal-title":"J Intensive Care"},{"key":"1170_CR20","unstructured":"Doi Y, Kondo M, Ando M, Kuwatsuka Y, Ishihara T. COVID-19 Nafamostat Observational Study in Japan: Preliminary Report. Japan; 2020."},{"key":"1170_CR21","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/0306-3623(95)00072-0","volume":"26","author":"S Muto","year":"1995","unstructured":"Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol. 1995;26:1627\u201332.","journal-title":"Gen Pharmacol"},{"key":"1170_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJM199503093321018","volume":"332","author":"H Kitagawa","year":"1995","unstructured":"Kitagawa H, Chang H, Fujita T. Hyperkalemia due to nafamostat mesylate. N Engl J Med. 1995;332:687.","journal-title":"N Engl J Med"},{"key":"1170_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5301\/ijao.5000451","volume":"38","author":"J-H Park","year":"2015","unstructured":"Park J-H, Her C, Min H-K, Kim D-K, Park S-H, Jang H-J. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. Int J Artif Organs. 2015;38:595\u20139.","journal-title":"Int J Artif Organs"},{"key":"1170_CR24","doi-asserted-by":"crossref","unstructured":"Ookawara S, Saitoh M, Yahagi T, Tabei K, Asano Y. Two cases of nafamostat mesilate-induced hyperkalemia. Jpn Soc Dial Ther. 1995;28.","DOI":"10.4009\/jsdt.28.1269"},{"key":"1170_CR25","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.12998\/wjcc.v8.i21.5320","volume":"8","author":"M Okajima","year":"2020","unstructured":"Okajima M, Takahashi Y, Kaji T, Ogawa N, Mouri H. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: four case reports. World J Clin Cases. 2020;8:5320\u20135.","journal-title":"World J Clin Cases."},{"key":"1170_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1476-5381.1994.tb14040.x","volume":"111","author":"S Muto","year":"1994","unstructured":"Muto S, Imai M, Asano Y. Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br J Pharmacol. 1994;111:173\u20138.","journal-title":"Br J Pharmacol"},{"key":"1170_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s002280050176","volume":"51","author":"S Ookawara","year":"1996","unstructured":"Ookawara S, Tabei K, Sakurai T, Sakairi Y, Furuya H, Asano Y. Additional mechanisms of nafamostat mesilate-associated hyperkalaemia. Eur J Clin Pharmacol. 1996;51:149\u201351.","journal-title":"Eur J Clin Pharmacol"},{"key":"1170_CR28","doi-asserted-by":"crossref","unstructured":"Quinn TM, Gaughan EE, Bruce A, Antonelli J, O\u2019Connor R, Li F, et al. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b\/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. eBioMedicine [Internet]. 2022;76:103856. http:\/\/medrxiv.org\/content\/early\/2021\/10\/07\/2021.10.06.21264648.abstract","DOI":"10.1016\/j.ebiom.2022.103856"},{"key":"1170_CR29","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1248\/bpb.31.1985","volume":"31","author":"Y-G Cao","year":"2008","unstructured":"Cao Y-G, Chen Y-C, Hao K, Zhang M, Liu X-Q. An in vivo approach for globally estimating the drug flow between blood and tissue for Nafamostat Mesilate: the main hydrolysis site determination in human. Biol Pharm Bull. 2008;31:1985\u20139.","journal-title":"Biol Pharm Bull"},{"key":"1170_CR30","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses. 2020;12.","DOI":"10.3390\/v12060629"},{"key":"1170_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Schroeder S, Kleine-Weber H, M\u00fcller MA, Drosten C, P\u00f6hlmann S. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64:19\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"1170_CR32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","volume":"32","author":"P Li","year":"2022","unstructured":"Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32:322\u20134.","journal-title":"Cell Res"},{"key":"1170_CR33","doi-asserted-by":"crossref","unstructured":"Doi K, Ikeda M, Hayase N, Moriya K, Morimura N, Maehara H, et al. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care. 2020;24.","DOI":"10.1186\/s13054-020-03078-z"},{"key":"1170_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ijid.2020.05.072","volume":"96","author":"S Jang","year":"2020","unstructured":"Jang S, Rhee J. Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. Int J Infect Dis. 2020;96:500\u20132.","journal-title":"Int J Infect Dis"},{"key":"1170_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1010260","volume":"18","author":"A Mittal","year":"2022","unstructured":"Mittal A, Khattri A, Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. PLoS Pathog. 2022;18:1\u201325. https:\/\/doi.org\/10.1371\/journal.ppat.1010260.","journal-title":"PLoS Pathog"},{"key":"1170_CR36","doi-asserted-by":"crossref","unstructured":"Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. Springer US; 2021;602:671\u20135.","DOI":"10.1038\/s41586-021-04389-z"},{"key":"1170_CR37","unstructured":"Meng B, Ferreira IAT., Abdullahi A, Saito A, Kimura I, Yamasoba D, et al. SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv [Internet]. 2021; https:\/\/www.biorxiv.org\/content\/10.1101\/2021.12.17.473248v2"},{"key":"1170_CR38","unstructured":"Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature. 2022;"},{"key":"1170_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41422-022-00619-9","volume":"32","author":"D Bojkova","year":"2022","unstructured":"Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res. 2022;32:319\u201321.","journal-title":"Cell Res"},{"key":"1170_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ijid.2020.10.093","volume":"102","author":"W Takahashi","year":"2021","unstructured":"Takahashi W, Yoneda T, Koba H, Ueda T, Tsuji N, Ogawa H, et al. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. Int J Infect Dis [Internet]. 2021;102:529\u201331. https:\/\/doi.org\/10.1016\/j.ijid.2020.10.093.","journal-title":"Int J Infect Dis [Internet]."},{"key":"1170_CR41","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jiac.2020.08.001","volume":"26","author":"S Iwasaka","year":"2020","unstructured":"Iwasaka S, Shono Y, Tokuda K, Nakashima K, Yamamoto Y, Maki J, et al. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. J Infect Chemother [Internet]. 2020;26:1319\u201323. https:\/\/doi.org\/10.1016\/j.jiac.2020.08.001 (Elsevier Ltd).","journal-title":"J Infect Chemother [Internet]."},{"key":"1170_CR42","doi-asserted-by":"crossref","unstructured":"Hifumi T, Isokawa S, Otani N, Ishimatsu S. Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients. Crit Care 2020;24.","DOI":"10.1186\/s13054-020-03227-4"},{"key":"1170_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/11795484211073273","volume":"16","author":"N Koriyama","year":"2022","unstructured":"Koriyama N, Moriuchi A, Higashi K, Kataoka T, Arimizu T, Takaguchi G, et al. COVID-19 with rapid progression to hypoxemia likely due to imbalance between ventilation and blood flow: a case report. Clin Med Insights Circ Respir Pulm Med. 2022;16:1\u20137.","journal-title":"Clin Med Insights Circ Respir Pulm Med."},{"key":"1170_CR44","doi-asserted-by":"crossref","unstructured":"Inokuchi R, Kuno T, Komiyama J, Uda K, Miyamoto Y, Taniguchi Y, et al. Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study. J Clin Med. 2022;11","DOI":"10.3390\/jcm11010116"},{"key":"1170_CR45","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.eclinm.2021.101169","volume":"41","author":"SV Zhuravel","year":"2021","unstructured":"Zhuravel SV, Khmelnitskiy OK, Burlaka OO, Gritsan AI, Goloshchekin BM, Kim S, et al. Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial. EClinicalMedicine. 2021;41:101169. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101169 (Elsevier Ltd).","journal-title":"EClinicalMedicine."},{"key":"1170_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5301\/ijao.5000191","volume":"36","author":"SD Hwang","year":"2013","unstructured":"Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J Artif Organs. 2013;36:208\u201316.","journal-title":"Int J Artif Organs"},{"key":"1170_CR47","first-page":"1","volume":"9","author":"YK Lee","year":"2014","unstructured":"Lee YK, Lee HW, Choi KH, Kim BS. Ability of Nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE. 2014;9:1\u20138.","journal-title":"PLoS ONE"},{"key":"1170_CR48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5694\/mja2.51143","volume":"215","author":"AC Bowen","year":"2021","unstructured":"Bowen AC, Tong SYC, Davis JS. Australia needs a prioritised national research strategy for clinical trials in a pandemic: lessons learned from COVID-19. Med J Aust. 2021;215:56-58.e1.","journal-title":"Med J Aust"},{"key":"1170_CR49","first-page":"319","volume":"32","author":"M Ramanan","year":"2022","unstructured":"Ramanan M, Tong SYC, Kumar A, Venkatesh B. Geographical representation of low- and middle-income countries in randomized clinical trials for COVID-19. JAMA Netw Open. 2022;32:319\u201321.","journal-title":"JAMA Netw Open"},{"key":"1170_CR50","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1186\/s13063-021-05760-1","volume":"22","author":"K Moon","year":"2021","unstructured":"Moon K, Hong K, Bae I. Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia\u202f: study protocol for a randomized controlled trial. Trials. 2021;22:832.","journal-title":"Trials"},{"key":"1170_CR51","first-page":"1","volume":"3","author":"J Rhee","year":"2021","unstructured":"Rhee J. A review of the possibility of Nafamostat Mesylate in COVID-19 treatment. J Cell Immunol. 2021;3:1\u20137.","journal-title":"J Cell Immunol."},{"key":"1170_CR52","unstructured":"EUnetHTA Rolling Collaborative Review (RCR05) Authoring Team. Nafamostat for the treatment of COVID-19. Report No: RCR05, v. 7.0 [Internet]. Diemen (The Netherlands); 2021. https:\/\/www.eunethta.eu\/wp-content\/uploads\/2021\/05\/EUnetHTA-Covid-19_RCR05_Nafamostat_V7.0.pdf"},{"key":"1170_CR53","doi-asserted-by":"publisher","unstructured":"Denholm JT, Venkatesh B, Davis J, Bowen AC, Hammond NE, Jha V, et al. ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. Res Sq. 2022;1\u201320. https:\/\/doi.org\/10.21203\/rs.3.rs-1045085\/v1","DOI":"10.21203\/rs.3.rs-1045085\/v1"},{"key":"1170_CR54","doi-asserted-by":"crossref","unstructured":"Jitobaom K, Boonarkart C, Manopwisedjaroen S, Punyadee N, Borwornpinyo S, Thitithanyanont A, et al. Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2. Res Sq. 2021","DOI":"10.21203\/rs.3.rs-941811\/v1"},{"key":"1170_CR55","doi-asserted-by":"publisher","unstructured":"Ellinger B, Bojkova D, Zaliani A, Cinatl J, Claussen C, Westhaus S, et al. A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Sci Data [Internet]. Springer US; 2021;8:1\u201311. https:\/\/doi.org\/10.1038\/s41597-021-00848-4","DOI":"10.1038\/s41597-021-00848-4"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01170-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01170-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01170-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:38:21Z","timestamp":1665542301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01170-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01170-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"7 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions.\nJason A. Roberts would like to acknowledge funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP2007007) and an Investigator Grant (APP2009736) as well as an Advancing Queensland Clinical Fellowship. Asha C. Bowen received salary support from the Australian National Health and Medical Research Council Investigator Award (GNT1175509).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The following authors Steven Y.C. Tong, Justin T. Denholm, Gregory J. Dore, Asha C. Bowen, Sharon R. Lewin, Balasubramanian Venkatesh, Thomas E. Hills, Zoe McQuilten, David L. Paterson, Susan C. Morpeth and Jason A. Roberts are members of the Australasian COVID-19 Trial (ASCOT), which is studying nafamostat as an antiviral treatment for non-critically ill, hospitalised COVID-19 patients. ASCOT has received nafamostat drug and an unrestricted investigator-initiated grant from manufacturer Chong Kun Dang Pharmaceuticals (Seoul, Korea) and Institute Pasteur Korea. ASCOT is supported by the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE), The BHP Foundation, Health Research Council of New Zealand, Hospital Research Foundation, The Macquarie Group Foundation, The Minderoo Foundation, The Pratt Foundation, Royal Brisbane and Women\u2019s Hospital Foundation, The Common Good (The Prince Charles Hospital Foundation), Wesley Medical Research, Chong Kun Dang Pharmaceutical Corporation, NSW Office for Health and Medical Research, Medical Research Future Fund (grant MRF2002132) and the Russell and Womersley Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the work presented in this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}